30 completed, 1 unknown, 1 withdrawn. 20 Phase 1, 10 Phase 2, 2 Phase 3.
By phase and status
Follow danoprevir: new trials by email Literature Review of danoprevir trials Research Report on danoprevir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C
Direct-acting antiviral agents - Hepatitis C, Chronic | | Unknown | 300 | 2019-03-06 | 2021-07-07 |
Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China
Danoprevir, Ritonavir, Ravidasvir - HCV | Phase 1 | Completed | 18 | 2017-08-08 | 2018-01-17 |
Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.
Ravidasvir, Danoprevir, Ritonavir - HCV | Phase 2 / Phase 3 | Completed | 425 | 2017-07-01 | 2020-07-28 |
Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers China
Ravidasvir, Danoprevir, Ritonavir - Healthy | Phase 1 | Completed | 18 | 2016-07-15 | 2018-06-29 |
Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III
Danoprevir, Ritonavir, peginterferon alfa-2a - Chronic Hepatitis C | Phase 3 | Completed | 141 | 2016-06-01 | 2021-03-23 |
Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II
Danoprevir, Ritonavir, peginterferon alfa-2a - Chronic Hepatitis C | Phase 2 | Completed | 70 | 2016-01-01 | 2018-07-26 |
Safety, Tolerability and Pharmacokinetics of Danoprevir/r in Healthy Volunteers China
Danoprevir, Ritonavir, Placebo - Healthy | Phase 1 | Completed | 18 | 2015-10-01 | 2017-01-13 |
Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan
Ravidasvir, Danoprevir, Ritonavir - Chronic Hepatitis C | Phase 2 | Completed | 38 | 2015-08-01 | 2020-10-22 |
A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis
danoprevir + ritonavir, peginterferon alfa-2a [Pegasys], ribavirin [Copegus] - Hepatitis C, Chronic | Phase 2 | Completed | 61 | 2013-04-01 | 2016-11-02 |
A Safety And Pharmacokinetic Study of Setrobuvir Alone and In Combination With Ritonavir-Boosted Danoprevir in Subjects With Mild Hepatic Impairment Compared to Healthy Controls
danoprevir, ritonavir, setrobuvir - Healthy Volunteer | Phase 1 | Completed | 18 | 2012-11-01 | 2016-11-02 |
A Pharmacokinetic And Bioavailability Study of Intravenous Danoprevir in Healthy Volunteers
danoprevir, placebo, ritonavir - Healthy Volunteer | Phase 1 | Completed | 33 | 2012-07-01 | 2016-11-02 |
A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment
RO5024048, danoprevir, peginterferon alfa-2a [Pegasys] - Hepatitis C, Chronic | Phase 2 | Withdrawn | | 2012-07-01 | 2016-11-02 |
A Study of Drug-Drug Interaction Between Danoprevir Coadministered With Low-Dose Ritonavir and Tenofovir Disoproxil Fumarate or Atazanavir
atazanavir, danoprevir, ritonavir - Healthy Volunteer | Phase 1 | Completed | 40 | 2012-05-01 | 2016-11-02 |
A Study of The Relative Bioavailability of Ritonavir-Boosted Danoprevir Fixed Dose Combination Tablets in Healthy Volunteers
danoprevir, ritonavir - Healthy Volunteer | Phase 1 | Completed | 42 | 2012-05-01 | 2016-11-02 |
A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis
RO5024048, danoprevir, peginterferon alfa-2a [Pegasys] - Hepatitis C, Chronic | Phase 2 | Completed | 43 | 2012-04-01 | 2016-08-01 |
A Study of Potential Drug-Drug Interaction Between Efavirenz and Danoprevir With Low Dose Ritonavir in Healthy Volunteers
danoprevir, efavirenz, ritonavir - Healthy Volunteer | Phase 1 | Completed | 40 | 2012-04-01 | 2016-11-02 |
A Study of Drug-Drug Interaction Between Darunavir and Danoprevir Administered Together With Low-Dose Ritonavir in Healthy Volunteers
danoprevir, darunavir, ritonavir - Healthy Volunteer | Phase 1 | Completed | 40 | 2012-02-01 | 2016-11-02 |
A Study of Drug-Drug Interaction Between Danoprevir/Low-Dose Ritonavir and Raltegravir in Healthy Volunteers
danoprevir, raltegravir, ritonavir - Healthy Volunteer | Phase 1 | Completed | 20 | 2012-01-01 | 2016-11-02 |
A Drug-Drug Interaction Study Between Danoprevir/Low-Dose Ritonavir and Cyclosporine in Healthy Volunteers
cyclosporine, danoprevir, ritonavir - Healthy Volunteer | Phase 1 | Completed | 18 | 2011-12-01 | 2016-11-02 |
A Relative Bioavailability Study of Danoprevir and Ritonavir in Healthy Volunteers
danoprevir, ritonavir - Healthy Volunteer | Phase 1 | Completed | 36 | 2011-12-01 | 2016-11-02 |
Showing 20 of 32. Sign in to see all of them.
Conditions studied
Hepatitis C, Chronic (13)
Sponsors
Hoffmann-La Roche (24) · Ascletis Pharmaceuticals Co., Ltd. (7) · Qing XIe (1)
Countries
United States (15) · France (7) · New Zealand (6) · Australia (4) · Canada (4) · Germany (4) · Poland (4) · Austria (3) · China (3) · Italy (3) · Brazil (2) · Mexico (2) · Puerto Rico (2) · Slovakia (2) · Spain (2)
Top investigators
Huoling Tang, PhD (5) · Qing Xie, MD (1) · Yahong Chen, Master (1)
Results publications
PMID 20951424, PMID 21354234, PMID 23712757, PMID 23811112, PMID 23872824, PMID 24295986, PMID 24637689, PMID 31608213, PMID 34252301
NIH funding
2009 (2)